Latigo Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Latigo Biotherapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-173.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
Latigo Biotherapeutics, Inc. made a loss over the last year. Latigo Biotherapeutics, Inc. owes $5.26 for every $1 it owns. Latigo Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLatigo Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-3.61Latigo Biotherapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$996 MThe total market value of all of Latigo Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeLatigo Biotherapeutics, Inc.'s net worth is negative ($276 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
5.26×Latigo Biotherapeutics, Inc. owes $5.26 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Dividend yield
NoneLatigo Biotherapeutics, Inc. does not currently pay a dividend.
Profit growth
LossLatigo Biotherapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashLatigo Biotherapeutics, Inc. held $69 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Latigo Biotherapeutics, Inc. owe compared with what it owns?
Latigo Biotherapeutics, Inc. owes $5.26 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Does Latigo Biotherapeutics, Inc. pay a dividend?
No. Latigo Biotherapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.